Su et al. [31] reported that high FOXD2-AS1 expression was associated with T stage and recurrence, but not with lymph node metastasis and differentiation, and overexpression of FOXD2-AS1 was related to poor overall survival (OS) and disease-free survival (DFS) in bladder cancer. This evidence concerns the gene FOXD2 and urinary bladder carcinoma.